A61M1/362

Processing blood

Methods (300), devices, and systems of processing blood are described. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting (314) bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

Processing blood

Methods (300), devices, and systems of processing blood are described. The method (300) comprises the steps of: obtaining (312) blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting (314) bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching (316) concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

MAGNETIC FILTER APPARATUS AND METHOD

A hemofilter system. In one embodiment, the hemofilter system includes a container having a first surface, a second surface, and one or more wall surfaces, the first surface, the second surface and the one or more wall surfaces defining a volume; an input port in fluid communication with the first surface; an output port in fluid communication with the second surface; a filter bed comprising a plurality of planar magnetic meshes stacked in close juxtaposition and positioned within the container volume and coplanar with the first and second surfaces; a first magnet positioned on a first surface of the container; a second magnet positioned on the second surface of the container; a first input conduit in fluid communication with the input port; and a first output conduit in fluid communication with the output port. In another embodiment, the hemofilter system includes a pump in the input conduit.

MATERIAL FOR REMOVING ACTIVATED LEUKOCYTE-ACTIVATED PLATELET COMPLEX

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

Systems and methods for parallel channel microfluidic separation

The present disclosure describes a system and method for microfluidic separation. More particularly, the disclosure describes a system and method for the purification of a fluid by the removal of undesired particles. The device includes microfluidic separation channels that include multiple outlets. The device also includes isolation slots positioned between each of the microfluidic separation channels. The device's base includes multiple acoustic transducers which in some implementations are configured to protrude into the isolation slots. The acoustic transducers are configured to generate aggregation axes within the separation channels, which are used to separate out undesired particles.

INDWELLING INTRAVASCULAR APHAERETIC SYSTEM FOR IN VIVO ENRICHMENT OF CIRCULATING TUMOR CELLS
20210060229 · 2021-03-04 ·

An apparatus for capturing circulating tumor cells (CTCs) from blood. The apparatus includes a wearable device that receives fluid from vasculature of a subject through an input channel. A pump is coupled to the input channel the pump configured to receive blood at a first flow rate and to convert the flow of the blood to a second flow rate. The device further includes a replaceable candidate cell capture module having a microfluidic capture stage with herringbone channel structures configured to capture the candidate cells by antibodies. The device is further configured to provide the blood back to the vasculature of the subject.

Material for capturing circulating cells in the blood, method of preparation and use

A material chosen from alumina ceramic grafted with at least one aptamer, at least one antibody or their combination for capturing circulating foreign cells, preferably circulating tumor cells, the method of preparing such material, its use and the device comprising it are disclosed.

Material for removing activated leukocyte-activated platelet complex

An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.

DEVICE FOR BINDING AND SEPARATION OF AT LEAST ONE COMPONENT FROM A BODY FLUID
20240001017 · 2024-01-04 ·

A device for binding and separation of at least one component from a body fluid is disclosed. The device may have a proximal end and a distal end. The device may include a housing, an inlet disposed at the proximal end, an outlet, at least one of a sheet and a disc of a first matrix for binding of a first component from the body fluid, and a plurality of beads of a second matrix for binding of a second component from the body fluid. The first matrix may have a porous structure. The first component and the second component may be one of the same and different.

GALECTIN-3 PLASMAPHERESIS THERAPY
20210001032 · 2021-01-07 · ·

A system and method for the practice of apheresis employs modules in the system which can be selected for a particular patient to treat particular situations or combinations of difficulties. In one example, Gal-3 mediates a large number of body reactions, and is an effective protector of tumor microenvironments and the like, as well inflammation driver. Removal of Gal-3 may make antic-cancer treatments, like photopheresis and TNF administration more effective. Separate modules, such as one for photopheresis and one for TNF receptor removal, may be combined with a module for the reduction of Gal-3, to render the combination of treatments each more effective than if administered alone.